A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
This study has been completed.
AbbVie (prior sponsor, Abbott)
First Posted: December 4, 2006
Last Update Posted: November 6, 2017
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||October 2016|
|Primary Completion Date:||October 2016 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Submission:||October 31, 2017|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, Enschede SH, Humerickhouse RA. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010 Dec;11(12):1149-59. doi: 10.1016/S1470-2045(10)70261-8. Epub 2010 Nov 18.